To evaluate the potential of indisulam to inhibit tumor growth in HNSCC, we first investigated the expression levels of RBM39, a critical target of indisulam, and its relationship with the splicing burden in patient samples. The gene discussed is RBM39; the disease is head and neck squamous cell carcinoma.